KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies.

Helena Marzo-Ortega, Victoria Navarro-Compan, Maureen Dubreuil, Philip J Mease, Marina Magrey, Martin Rudwaleit, Maria-Antonietta D'Agostino, Karl Gaffney, Jonathan Kay, Christine de la Loge, Ute Massow, Vanessa Taieb, Tom Vaux, Atul Deodhar

RMD Open 11(4) e006013

PMID41314667
PMCIDPMC12706112
DOI10.1136/rmdopen-2025-006013
发表日期2025-11-28
入排依据:未发现恶性肿瘤人群证据。
已检查 8 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other;另有 3 张未列出。
摘要

摘要

OBJECTIVE: To assess the long-term effect of bimekizumab, a dual inhibitor of IL-17A and IL-17F, on patient-reported symptoms, function and health-related quality of life (HRQoL) in patients with axial spondyloarthritis (axSpA) from phase 3 studies and their open-label extension. METHODS: BE MOBILE 1 (non-radiographic-axSpA) and 2 (radiographic-axSpA) comprised 16-week double-blind placebo-controlled and 36-week maintenance periods. From week 16, all patients received subcutaneous bimekizumab 160 mg every 4 weeks. At week 52, eligible patients could enrol in the open-label extension BE MOVING and continue bimekizumab treatment. Spinal pain (rated on a numerical rating scale from 0 (no pain) to 10 (maximum pain)), morning stiffness (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) average of Q5/6), fatigue (BASDAI Q1; Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue subscale), sleep quality (Medical Outcomes Study (MOS) Sleep Scale Index II), physical function (Bath Ankylosing Spondylitis Functional Index (BASFI)) and HRQoL (36-Item Short Form Survey (SF-36) physical component summary (PCS)/mental component summary (MCS); Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire) were reported to week 104. RESULTS: In total, 494/586 (84.3%) patients entered BE MOVING at week 52; 456 completed week 104. Patients reported substantial changes from baseline to week 104 in total spinal pain (-4.3), nocturnal spinal pain (-4.3), morning stiffness (-4.3) and fatigue (BASDAI Q1: -3.4; FACIT-Fatigue: +9.9). Over half reported total and nocturnal spinal pain scores ≤3 at week 104. Similar improvements to week 104 were shown in sleep (MOS-Sleep Scale: +10.2), physical function (BASFI: -2.9) and HRQoL (SF-36 PCS: +12.4; ASQoL: -5.6). CONCLUSIONS: Bimekizumab treatment resulted in sustained improvements in patient-reported symptoms and their impacts across the full disease spectrum of axSpA over 2 years, underscoring its long-term potential for improving patients' daily lives. TRIAL REGISTRATION NUMBERS: NCT03928704, NCT03928743, NCT04436640.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(8,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Mean improvement in spinal pain and morning stiffness (MI), as rated on an NRS (0–10) Pooled randomised set. Error bars represent 95% CI. Improvement indicated by decreased scores; patients were asked to consider the average amount of pain or morning stiffness in the preceding week. a Includes all patients regardless of randomisation to BKZ or PBO. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BKZ, bimekizumab; CfB, change from baseline; MI, multiple imputation; NRS, numerical rating scale; PBO, placebo; Q5/6, question 5/6; Q4W, every 4 weeks.
非 KM Figure
Figure 2Figure 2 Proportion of patients achieving thresholds for low spinal pain or morning stiffness at week 104 (NRI, OC), as rated on an NRS (0–10). Pooled randomised set: includes all patients regardless of randomisation to BKZ or placebo. Improvement indicated by decreased scores; patients were asked to consider the average amount of pain or morning stiffness in the preceding week. BKZ, bimekizumab; NRI, non-responder imputation; NRS, numerical rating scale; OC, observed case; Q4W, every 4 weeks.
非 KM Figure
Figure 3Figure 3 Mean improvement in fatigue, as measured by BASDAI Q1 and FACIT-Fatigue (MI). Pooled randomised set. Error bars represent 95% CI. Improvement indicated by decreased scores for BASDAI Q1 (range: 0–10) and increased scores for FACIT-Fatigue (range: 0–52). a Includes all patients regardless of randomisation to BKZ or PBO. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BKZ, bimekizumab; CfB, change from baseline; FACIT, Functional Assessment of Chronic Illness Therapy; MI, multiple imputation; PBO, placebo; Q1, question 1; Q4W, every 4 weeks.
非 KM Figure
Figure 4Figure 4 Proportion of patients achieving A) fatigue severity thresholds, as measured by BASDAI Q1 (MI) and B) meaningful improvement in fatigue, assessed as a ≥8-point improvement in FACIT-Fatigue (NRI, OC). Pooled randomised set (N=586): includes all patients regardless of randomisation to BKZ or placebo. a Analysis includes patients with a FACIT-Fatigue score ≤44 at baseline (n=520). BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BKZ, bimekizumab; FACIT, Functional Assessment of Chronic Illness Therapy; MI, multiple imputation; NRI, non-responder imputation; OC, observed case; Q1, question 1; Q4W, every 4 weeks.
非 KM Figure
Figure 5Figure 5 Mean improvement in physical function (MI) and proportion of patients achieving thresholds for low impairment of physical function at week 104, as measured by BASFI (NRI, OC) Pooled randomised set. Error bars represent 95% CI. CfB improvements indicated by decreased scores (range: 0–10). a Includes all patients regardless of randomisation to BKZ or PBO. BASFI, Bath Ankylosing Spondylitis Functional Index; BKZ, bimekizumab; CfB, change from baseline; MI, multiple imputation; NRI, non-responder imputation; OC, observed case; PBO, placebo; Q4W, every 4 weeks.
非 KM Figure
Figure 6Figure 6 Mean improvement in HRQoL (MI), as measured by SF-36 PCS and ASQoL. Pooled randomised set. Error bars represent 95% CI. Improvements indicated by increased scores for SF-36 PCS. Improvements indicated by decreased scores for ASQoL (range: 0–18). a For SF-36 PCS, group-level mean scores between 47 and 53 (blue shaded area) can be considered within the ‘average’ or ‘normal’ range for the US general population (mean score in US general population is 50 (SD:10)). b Includes all patients regardless of randomisation to BKZ or PBO. ASQoL, Ankylosing Spondylitis Quality of Life; BKZ, bimekizumab; CfB, change from baseline; HRQoL, health-related quality of life; MI, multiple imputation; PBO, placebo; Q4W, every 4 weeks; SF-36 PCS, 36-Item Short Form Survey Physical Component Summary.
非 KM Figure
Figure 7Figure 7 Proportion of patients achieving meaningful improvements in HRQoL, as measured by SF-36 PCS and ASQoL (NRI, OC). Pooled randomised set: includes all patients regardless of randomisation to BKZ or PBO. Improvements indicated by increased scores for SF-36 PCS. Improvements indicated by decreased scores for ASQoL (range: 0–18). a Analysis includes patients with ASQoL score ≥4 at baseline. ASQoL, Ankylosing Spondylitis Quality of Life; BKZ, bimekizumab; HRQoL, health-related quality of life; NRI, non-responder imputation; OC, observed case; PBO: placebo; Q4W, every 4 weeks; SF-36 PCS, 36-Item Short Form Survey Physical Component Summary.
非 KM Figure
Figure 8Figure 8 Proportion of patients responding ‘yes’ to individual ASQoL items at baseline and weeks 52 and 104 (OC). Pooled randomised set (N=586): includes all patients regardless of randomisation to bimekizumab or PBO. Items are ordered by decreasing percentage of patients reporting ‘yes’ at baseline. ASQoL, Ankylosing Spondylitis Quality of Life; OC: observed case; PBO: placebo.
非 KM Figure